173 related articles for article (PubMed ID: 19447172)
21. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.
Desai D; Salli U; Vrana KE; Amin S
Bioorg Med Chem Lett; 2010 Mar; 20(6):2044-7. PubMed ID: 20167479
[TBL] [Abstract][Full Text] [Related]
22. Non-hydroxamate histone deacetylase inhibitors.
Suzuki T; Miyata N
Curr Med Chem; 2005; 12(24):2867-80. PubMed ID: 16305476
[TBL] [Abstract][Full Text] [Related]
23. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
24. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
25. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo.
Dincman TA; Beare JE; Ohri SS; Gallo V; Hetman M; Whittemore SR
Int J Dev Neurosci; 2016 Nov; 54():53-61. PubMed ID: 27587342
[TBL] [Abstract][Full Text] [Related]
27. QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids.
Wang DF; Wiest O; Helquist P; Lan-Hargest HY; Wiech NL
Bioorg Med Chem Lett; 2004 Feb; 14(3):707-11. PubMed ID: 14741273
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma.
Carbajo-García MC; García-Alcázar Z; Corachán A; Monleón J; Trelis A; Faus A; Pellicer A; Ferrero H
Fertil Steril; 2022 Feb; 117(2):433-443. PubMed ID: 34809976
[TBL] [Abstract][Full Text] [Related]
29. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
Li D; Marchenko ND; Moll UM
Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
[TBL] [Abstract][Full Text] [Related]
30. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).
Hendricks JA; Keliher EJ; Marinelli B; Reiner T; Weissleder R; Mazitschek R
J Med Chem; 2011 Aug; 54(15):5576-82. PubMed ID: 21721525
[TBL] [Abstract][Full Text] [Related]
31. The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
Choi SE; Pflum MK
Bioorg Med Chem Lett; 2012 Dec; 22(23):7084-6. PubMed ID: 23089527
[TBL] [Abstract][Full Text] [Related]
32. The Histone-Deacetylase-Inhibitor Suberoylanilide Hydroxamic Acid Promotes Dental Pulp Repair Mechanisms Through Modulation of Matrix Metalloproteinase-13 Activity.
Duncan HF; Smith AJ; Fleming GJ; Partridge NC; Shimizu E; Moran GP; Cooper PR
J Cell Physiol; 2016 Apr; 231(4):798-816. PubMed ID: 26264761
[TBL] [Abstract][Full Text] [Related]
33. Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells.
Dong G; Luo J; Kumar V; Dong Z
Am J Physiol Renal Physiol; 2010 Feb; 298(2):F293-300. PubMed ID: 19889954
[TBL] [Abstract][Full Text] [Related]
34. Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction network.
Sardiu ME; Smith KT; Groppe BD; Gilmore JM; Saraf A; Egidy R; Peak A; Seidel CW; Florens L; Workman JL; Washburn MP
Mol Cell Proteomics; 2014 Nov; 13(11):3114-25. PubMed ID: 25073741
[TBL] [Abstract][Full Text] [Related]
35. REST is a novel prognostic factor and therapeutic target for medulloblastoma.
Taylor P; Fangusaro J; Rajaram V; Goldman S; Helenowski IB; MacDonald T; Hasselblatt M; Riedemann L; Laureano A; Cooper L; Gopalakrishnan V
Mol Cancer Ther; 2012 Aug; 11(8):1713-1723. PubMed ID: 22848092
[TBL] [Abstract][Full Text] [Related]
36. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
[TBL] [Abstract][Full Text] [Related]
38. Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression.
Butt NA; Kumar A; Dhar S; Rimando AM; Akhtar I; Hancock JC; Lage JM; Pound CR; Lewin JR; Gomez CR; Levenson AS
Cancer Med; 2017 Nov; 6(11):2673-2685. PubMed ID: 29024573
[TBL] [Abstract][Full Text] [Related]
39. The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA).
Marks PA
Cell Cycle; 2004 May; 3(5):534-5. PubMed ID: 15020838
[TBL] [Abstract][Full Text] [Related]
40. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice.
Hebbel RP; Vercellotti GM; Pace BS; Solovey AN; Kollander R; Abanonu CF; Nguyen J; Vineyard JV; Belcher JD; Abdulla F; Osifuye S; Eaton JW; Kelm RJ; Slungaard A
Blood; 2010 Mar; 115(12):2483-90. PubMed ID: 20053759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]